Skip to main content
. 2022 Sep 22;84:104245. doi: 10.1016/j.ebiom.2022.104245

Table 1.

Demographic information for the participants included in the study. Current health at T2 compared to before the earliest infection in the household was lower in infected adults than exposed adults and in infected adolescents than exposed adolescents; there was no difference for children; see text for details.

Adults
Adolescents 14-18
Children <14 years
Exposed Infected Exposed Infected Exposed Infected
N (% of age subgroup) 229 (31.7%) 494 (68.3%) 81 (57.9%) 59 (42.1%) 253 (62.6%) 151 (37.4%)
Study centre, N (% within age and infection status subgroup) Freiburg (145 households) 103 (45.0%) 208 (42.1%) 45 (55.6%) 19 (32.2%) 111 (43.9%) 58 (38.4%)
Heidelberg (49 households) 23 (10.0%) 73 (14.8%) 7 (8.6%) 13 (22.0%) 26 (10.3%) 22 (14.6%)
Tübingen (99 households) 68 (29.7%) 150 (30.4%) 19 (23.5%) 14 (23.7%) 87 (34.4) 43 (28.5%)
Ulm (48 households) 35 (15.3%) 63 (12.8%) 10 (12.3%) 13 (22.0%) 29 (11.5%) 28 (18.5%)
Male, N (%) 116 (50.7) 236 (47.8) 36 (44.4) 31 (52.5) 125 (49.4) 81 (53.6)
Age in years, median (Q1-Q3) 43 (35-50) 45 (39-50) 16 (15-17) 16 (14-17) 7 (4-10) 8 (5-11)
Days between earliest household infection and T2, median (IQR) 332 (315-366) 332 (312-361) 327 (314-350) 350 (314-377) 335 (313-358) 340 (307-369)
T2 Current health VAS score, median (IQR) 92 (82-100) 87 (80-95) 96 (88-100) 91 (80-100) 100 (94-100) 100 (94-100)
Pre-existing conditions, N (% of age and infection status subgroup) 85 (36.3%) 181 (36.2%) 13 (15.9%) 9 (15.3%) 15 (5.8%) 21 (13.9%)
Medication, N (% of age and infection status subgroup) 86 (37.6%) 168 (34.0%) 4 (4.9%) 6 (10.2%) 8 (3.2%) 8 (5.3%)